The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?
In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years.
“Five years after the initial accelerated approval, you should have a definitive answer,” said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not.”
The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs.
It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce better evidence before gaining full approval.
Inquiry slams UK authorities for failures that killed thousands in infected blood scandal
He's out! Monty Panesar pulls stumps on his bid to become an MP for George Galloway's party as ex
Intruder tries to break into Drake's house one day after his security guard was shot outside
Kristin Cavallari, 37, ignores critics of her age
Guns are being stolen from cars at triple the rate they were 10 years ago, a report finds
Scottish Power says our meters are too old
Philippines blames China for loss of giant clams in disputed shoal and urges environmental inquiry
Bella Hadid goes braless in a thigh
Winner of North Macedonia's parliamentary election to seek governing coalition partner